Novartis AG Company Description

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.

The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.

It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies.

The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Country	Switzerland
Founded	1996
Industry	Pharmaceutical Preparations
Employees	76,057
CEO	Vasant Narasimhan

Contact Details

Address: Lichtstrasse 35 Basel, 4056 Switzerland
Phone	41 61 324 1111
Website	novartis.com

Stock Details

Ticker Symbol	0K9E
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2834

Key Executives

Name	Position
Vasant Narasimhan	Chief Executive Officer
Harry Kirsch	Chief Financial Officer
Steffen Lang	Chief Operating Officer
Sloan Simpson	Head of Investor Relations